| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.7 | 0.0 |
| Net income | -7.7 | -5.4 |
| EPS (diluted, $ a share) | $-0.04 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RANI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rani Therapeutics Holdings, Inc.: key numbers
- Share price
- $0.5403Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rani Therapeutics Holdings, Inc.
All →Rani Therapeutics Holdings Nasdaq/NYSE Compliance Notice
Rani Therapeutics received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. As part of this process, the company's listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 12, 2026. The company now has until May 10, 2027, to meet the requirement, which may involve a reverse stock split if necessary.
- Counterparty
- Nasdaq
- Term
- 180 days
Rani Therapeutics Holdings Financial Results
Rani Therapeutics reported third quarter 2026 financial results and announced its acceptance into the FDA’s Emerging Technology Program to support the RaniPill platform. The company reported a cash position of $45.3 million, which it expects will fund operations through the end of 2027, and noted that enrollment continues for its RT-114 Phase 1a expansion cohort.
“The third quarter marked continued progress for the RaniPill® platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides an opportunity to engage with the Agency on technical, manufacturing and regulatory considerations related to the RaniPill® platform.”
Talat Imran, Chief Executive Officer of Rani Therapeutics
“With cash, cash equivalents and marketable securities of $45.3 million, we believe we are well positioned to fund operations at least through the end of 2027 and to execute on our priorities, including additional RT-114 data by year-end.”
Talat Imran, Chief Executive Officer of Rani Therapeutics